
Vivani Medical, Inc. (VANI) Stock Ticker
VANI right now
Market factors today
Unlock the full VANI picture
About Vivani Medical, Inc.
Vivani Medical, Inc., a clinical-stage biopharmaceutical company, engages in the development of miniaturized and subdermal drug implants that treat chronic diseases. The company uses its NanoPortal implant technology to develop and potentially commercialize drug implant candidates, alone or in collaboration with pharmaceutical company partners, to address causes of poor clinical outcomes in the treatment of chronic diseases. Its pipeline includes NPM-139 for chronic weight management in patients who are obese or overweight; NPM-133 a semaglutide implant for the treatment of patients with type 2 diabetes; NPM-115, an exenatide implant candidate for chronic weight management in patients who are obese or overweight; and OKV-119, an exenatide implant for the treatment of obesity and diabetes in companion animals, including cats and dogs. The company is headquartered in Alameda, California.
VANI stock facts
| Ticker symbol | VANI |
| Exchange | NASDAQ Capital Market |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market cap | $106.9M |
| CEO | Adam Mendelsohn |
| Employees | 42 |
| Headquarters | Alameda, CA, US |
| IPO date | 2014-11-19 |
| Website | www.vivani.com |
What you can see for VANI on Tickr
Live VANI price chart with overlays, the options chain, implied move, IV rank, options flow and Strategy Lab, financial statements and consensus estimates, analyst ratings, catalysts, news with AI scoring, and an AI chat that has read the VANI report.
Rankings
FAQ
What is the ticker symbol for Vivani Medical, Inc.?
The ticker symbol for Vivani Medical, Inc. is VANI, listed on the NASDAQ Capital Market.
What is VANI?
Vivani Medical, Inc., a clinical-stage biopharmaceutical company, engages in the development of miniaturized and subdermal drug implants that treat chronic diseases. The company uses its NanoPortal implant technology to develop and potentially commercialize drug implant candidates, alone or in collaboration with pharmaceutical company partners, to address causes of poor clinical outcomes in the…